UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jun 15, 2021
SOUTH PLAINFIELD, N.J. , June 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units ("RSUs"), each representing the
Additional Formats
Jun 11, 2021
- JEWELFISH results demonstrated stabilization in motor function in broad SMA population - - Evrysdi has proven efficacy in adults, children and babies two months and older - - Results presented at CureSMA Conference - SOUTH PLAINFIELD, N.J. , June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.
Additional Formats
Jun 09, 2021
SOUTH PLAINFIELD, N.J. , June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company's Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service , a $6
Additional Formats
May 26, 2021
SOUTH PLAINFIELD, N.J. , May 26, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with
Additional Formats
May 19, 2021
SOUTH PLAINFIELD, N.J. , May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41 st Annual Growth Stock Conference Wednesday, June 2 nd at 3:40 p.m.
Additional Formats
May 17, 2021
- Caregivers spend on average 15 hours a day providing care - SOUTH PLAINFIELD, N.J. , May 17, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid
Additional Formats
May 04, 2021
- PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Total net revenue of $118 million; 73% increase over first quarter 2020 - - DMD franchise net product revenue of $90 million; 32% increase over first quarter 2020 - - PTC has
Additional Formats
Apr 27, 2021
SOUTH PLAINFIELD, N.J. , April 27, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: BofA Securities 2021 Virtual Health Care Conference Tuesday, May 11 th at 8:45 a.m.
Additional Formats
Apr 20, 2021
SOUTH PLAINFIELD, N.J. , April 20, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tuesday, May 4, 2021
Additional Formats
Apr 19, 2021
SOUTH PLAINFIELD, N.J. , April 19, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units ("RSUs"), each representing
Additional Formats